Released date: January 1, 1970

EvolverAI Track Record

EvolverAI Track Record

Immunooncology program (licensed to BioXcel Therapeutics)
  • BXCL701, Oral Immunomodulator
    Solid tumors (Gastric, Head & Neck, TNBC, NSCLC)

    Initiate PD-1 Inhibitor synergy human proof-of-concept in Q2 2017
  • BXCL702, IV Immunomodulator
    Hematological Malignancies (AML, DLBC)

    Initiate PD-1 Inhibitor synergy human proof-of-concept in Q2 2017

ORPHAN/NEUROSCIENCE PROGRAM
  • BXCL101, Targets Proteasome Degradation
    Neurofibromatosis Type 2 (NF2) (developed by BioXcel Corporation)

    Granted ODD status by the U.S. FDA
    Proof-of-concept established in one patient
  • BXCL501, (licensed to BioXcel Therapeutics) Targets Hyperarousal Mechanism Acute Agitation

    Sublingual formulation
    Human proof of activity in 2017
  • Late stage 11 clinical programs from a large pharma
    Drug Re-Innovation

    Yielding multiple human proof of concept candidates

    BXCL901: Targets erythropoietic mechanisms
    Diamond Blackfan Anaemia (DBA)

    Initiate human proof of concept by H1 2017

    BXCL902: Targets respiratory irregularities Rett Syndrome

    Initiate human proof of concept by H1 2017

COLLABORATIONS
  • Centrexion : Development of Chronic Pain Therapies using real time Big Data Platform